PENTIXAPHARM
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
PENTIXAPHARM
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2019-01-01
Address:
Würzburg, Bayern, Germany
Country:
Germany
Website Url:
http://www.pentixapharm.com
Total Employee:
1+
Status:
Active
Total Funding:
15 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network JsDelivr Dynatrace
Similar Organizations
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Investors List
Eckert Life Science Accelerator
Eckert Life Science Accelerator investment in Series A - Pentixapharm
Official Site Inspections
http://www.pentixapharm.com Semrush global rank: 5.2 M Semrush visits lastest month: 1.56 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Pentixapharm"
About Us - Pentixapharm
Pentixapharm is a clinical-stage radiopharmaceutical development company founded in 2019 with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand …See details»
Pentixapharm Holding AG: Upcoming Changes in the …
Berlin, Germany, October 25, 2024 - Following the receipt of various approvals, consents, and registrations, Pentixapharm Holding AG will implement, at the end of October 2024, a series of …See details»
Pentixapharm - Crunchbase Company Profile & Funding
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a …See details»
Pentixapharm AG - Würzburg, Germany - bionity.com
Jul 16, 2024 Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. Its clinical pipeline encompasses PentixaTher, …See details»
Pentixapharm (Group) - life-sciences-europe.com
Oct 2, 2024 Pentixapharm AG is a clinical-stage radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is committed to developing …See details»
Pentixapharm AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pentixapharm AG of Würzburg, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
PentixaPharm Company Profile 2024: Stock Performance
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic …See details»
PentixaPharm - Overview, News & Similar companies - ZoomInfo
PentixaPharm contact info: Phone number: +49 93199136076 Website: www.pentixapharm.com What does PentixaPharm do? PentixaPharm, founded in 2019, is a radiopharmaceutical …See details»
Investors — Pentixapharm
Pentixapharm AG, a former subsidiary of Eckert & Ziegler Group, has successfully completed its spin-off into Pentixapharm Holding AG, followed by its listing on October 3, 2024, in the Prime …See details»
Pentixapharm - VentureRadar
PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals …See details»
PentixaPharm - Products, Competitors, Financials, Employees ...
PentixaPharm, a joint venture between Scintomics and 1717 Life Science Ventures, is committed to developing PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, …See details»
Pentixapharm: the radiopharmaceutical company with a head start …
Sep 5, 2024 Amid a surge in radiopharmaceutical investments, Pentixapharm, a subsidiary of Eckert & Ziegler Group, is set to spin off as an independent company listed on the Frankfurt …See details»
Radiopharmaceutical firm Pentixapharm raises $22M through …
Oct 7, 2024 Germany-based radiopharmaceutical firm Pentixapharm has raised nearly $22 million (USD) through an initial public stock offering, the company announced Oct. 1. The …See details»
Equity-Story — Pentixapharm
Spin-Off from Eckert & Ziegler SE Offers Exciting Opportunity in Radiopharmaceuticals. Pentixapharm has completed its spin-off and consecutive IPO on the Frankfurt Stock …See details»
Pentixapharm | EU-Startups
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic …See details»
What is PentixaPharm? Company Culture, Mission, Values
See what employees say it's like to work at PentixaPharm. Salaries, reviews, and more - all posted by employees working at PentixaPharm.See details»
Reports — Pentixapharm
Interim Financial Statements, Pentixapharm Holding AG - PDF (Only available in German) 2023. Consolidated Financial Statement, Pentixapharm AG - PDF (Only available in German) Annual …See details»
Pentixapharm scores $22M IPO to advance radiopharma trials
Oct 3, 2024 Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the proceeds to push ahead with the clinical development of …See details»
News - Pentixapharm
Oct 19, 2024 She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist …See details»